Financials Chimerix, Inc.

Equities

CMRX

US16934W1062

Biotechnology & Medical Research

Market Closed - Nasdaq 02:00:00 04/05/2024 am IST 5-day change 1st Jan Change
0.9529 USD +0.28% Intraday chart for Chimerix, Inc. +5.89% -1.00%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 124.6 302.5 558.5 163.8 85.56 85.41 - -
Enterprise Value (EV) 1 124.6 302.5 558.5 163.8 85.56 85.41 85.41 85.41
P/E ratio -1 x -6.9 x -3.15 x 0.96 x -1.03 x -1.03 x -0.94 x -1.29 x
Yield - - - - - - - -
Capitalization / Revenue 9.95 x 56.3 x 282 x 4.84 x 264 x 9.18 x 34.2 x 2.31 x
EV / Revenue 9.95 x 56.3 x 282 x 4.84 x 264 x 9.18 x 34.2 x 2.31 x
EV / EBITDA - - - - - - - -
EV / FCF - - -5.56 x -3.49 x - -0.99 x -0.96 x -1.14 x
FCF Yield - - -18% -28.7% - -101% -104% -87.8%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 61,382 62,634 86,862 88,045 88,891 89,630 - -
Reference price 2 2.030 4.830 6.430 1.860 0.9625 0.9529 0.9529 0.9529
Announcement Date 25/02/20 25/02/21 01/03/22 02/03/23 29/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 12.52 5.372 1.979 33.82 0.324 9.305 2.5 37.03
EBITDA - - - - - - - -
EBIT 1 -116 -44.52 -90.51 -60.39 -93.06 -89.47 -102.8 -81.88
Operating Margin -926.46% -828.67% -4,573.52% -178.53% -28,723.77% -961.49% -4,110.87% -221.13%
Earnings before Tax (EBT) 1 -112.6 -43.52 -173.2 172.2 -82.1 -82.37 -97.13 -77.39
Net income 1 -112.6 -43.52 -173.2 172.2 -82.1 -83.07 -97.13 -74.71
Net margin -899.24% -810.16% -8,753.71% 509.01% -25,337.96% -892.7% -3,885.31% -201.76%
EPS 2 -2.030 -0.7000 -2.040 1.940 -0.9300 -0.9267 -1.017 -0.7371
Free Cash Flow 1 - - -100.4 -46.94 - -86 -89 -75
FCF margin - - -5,075.19% -138.77% - -924.23% -3,560% -202.55%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 25/02/20 25/02/21 01/03/22 02/03/23 29/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.107 0.046 0.015 0.44 32.56 0.814 0.283 0.026 0.011 0.004 0.06 0.06 0.06 6.06 -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -18.6 -39.53 -24.77 -23.45 11.65 -23.81 -24.22 -21.35 -26.69 -20.81 -24.39 -23.7 -24.15 -17.03 -
Operating Margin -17,383.18% -85,939.13% -1,65,140% -5,328.86% 35.77% -2,925.55% -8,557.6% -82,107.69% -2,42,627.27% -5,20,250% -36,273.62% -39,504.77% -40,243.57% -281.01% -
Earnings before Tax (EBT) 1 -18.56 -39.5 -24.77 -23.47 241.5 -21.08 -21.37 -18.58 -23.99 -18.16 -21.87 -21.58 -22.12 -15.47 -
Net income 1 -18.56 -39.5 -24.77 -23.47 241.4 -20.96 -21.37 -18.58 -23.99 -18.16 -21.87 -21.58 -22.12 -15.47 -
Net margin -17,345.79% -85,865.22% -1,65,113.33% -5,333.64% 741.4% -2,574.94% -7,551.94% -71,446.15% -2,18,054.55% -4,54,025% -31,916.12% -35,962.15% -36,868.57% -255.21% -
EPS 2 -0.2100 -0.4500 -0.2800 -0.2700 2.750 -0.2400 -0.2400 -0.2100 -0.2700 -0.2000 -0.2500 -0.2357 -0.2457 -0.1729 -0.2300
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 04/11/21 01/03/22 16/05/22 08/08/22 03/11/22 02/03/23 04/05/23 03/08/23 02/11/23 29/02/24 01/05/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - -100 -46.9 - -86 -89 -75
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.16 0.06 0.21 0.07 - 0.06 0.05 0.05
Capex / Sales 1.26% 1.08% 10.46% 0.21% - 0.61% 2% 0.14%
Announcement Date 25/02/20 25/02/21 01/03/22 02/03/23 29/02/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.9529 USD
Average target price
7 USD
Spread / Average Target
+634.60%
Consensus
  1. Stock Market
  2. Equities
  3. CMRX Stock
  4. Financials Chimerix, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW